PD 173074 is a potent, selective small-molecule inhibitor of the protein kinase CK2, currently investigated for its potential in treating cancers associated with CK2 overexpression, such as glioblastoma… Read more
PD 173074 is a potent, selective small-molecule inhibitor of the protein kinase CK2, currently investigated for its potential in treating cancers associated with CK2 overexpression, such as glioblastoma and osteosarcoma. By antagonizing this kinase, the compound disrupts critical cellular pathways, including DNA repair and cell cycle progression. Pharmaceutical laboratories utilize associated analytical compounds—including degradation products, metabolites, and stable isotope-labelled standards—to ensure the integrity and accuracy of research and development workflows. These reference standards are essential for reliable impurity profiling, method validation, and precise quantification in bioanalytical assays using high-resolution mass spectrometry. By providing structurally characterized materials, these products facilitate rigorous quality control throughout the manufacturing lifecycle of the active pharmaceutical ingredient, helping chemists maintain consistency and compliance in analytical testing protocols.